BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 19482086)

  • 1. The angiogenic switch in carcinogenesis.
    Baeriswyl V; Christofori G
    Semin Cancer Biol; 2009 Oct; 19(5):329-37. PubMed ID: 19482086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch.
    Naumov GN; Akslen LA; Folkman J
    Cell Cycle; 2006 Aug; 5(16):1779-87. PubMed ID: 16931911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiangiogenic effects of marine sponge derived compounds on cancer.
    Senthilkumar K; Venkatesan J; Manivasagan P; Kim SK
    Environ Toxicol Pharmacol; 2013 Nov; 36(3):1097-108. PubMed ID: 24148290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications.
    Harper J; Moses MA
    EXS; 2006; (96):223-68. PubMed ID: 16383021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance.
    Cao Y; Zhong W; Sun Y
    Semin Cancer Biol; 2009 Oct; 19(5):338-43. PubMed ID: 19481151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dormant tumors awaken by a short-term angiogenic burst: the spike hypothesis.
    Indraccolo S; Favaro E; Amadori A
    Cell Cycle; 2006 Aug; 5(16):1751-5. PubMed ID: 16861908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The angiogenic switch: implications in the regulation of tumor dormancy.
    Moserle L; Amadori A; Indraccolo S
    Curr Mol Med; 2009 Nov; 9(8):935-41. PubMed ID: 19925406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redundant angiogenic signaling and tumor drug resistance.
    Gacche RN; Assaraf YG
    Drug Resist Updat; 2018 Jan; 36():47-76. PubMed ID: 29499837
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiogenic factors as potential drug target: efficacy and limitations of anti-angiogenic therapy.
    Gacche RN; Meshram RJ
    Biochim Biophys Acta; 2014 Aug; 1846(1):161-79. PubMed ID: 24836679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Classical and non-classical proangiogenic factors as a target of antiangiogenic therapy in tumor microenvironment.
    Marech I; Leporini C; Ammendola M; Porcelli M; Gadaleta CD; Russo E; De Sarro G; Ranieri G
    Cancer Lett; 2016 Sep; 380(1):216-26. PubMed ID: 26238184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new family of angiogenic factors.
    Martínez A
    Cancer Lett; 2006 May; 236(2):157-63. PubMed ID: 15927357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular regulation of tumor angiogenesis and perfusion via redox signaling.
    Miller TW; Isenberg JS; Roberts DD
    Chem Rev; 2009 Jul; 109(7):3099-124. PubMed ID: 19374334
    [No Abstract]   [Full Text] [Related]  

  • 14. Identification of novel drug targets for angiostatic cancer therapy; it takes two to tango.
    Thijssen VL; van Beijnum JR; Mayo KH; Griffioen AW
    Curr Pharm Des; 2007; 13(35):3576-83. PubMed ID: 18220794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenesis: molecular mechanisms of activation, promotion and maintenance.
    Bikfalvi A
    J BUON; 2007 Sep; 12 Suppl 1():S59-66. PubMed ID: 17935279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone morphogenetic proteins in tumour associated angiogenesis and implication in cancer therapies.
    Ye L; Jiang WG
    Cancer Lett; 2016 Oct; 380(2):586-597. PubMed ID: 26639195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenesis--a new target for future therapy.
    Pandya NM; Dhalla NS; Santani DD
    Vascul Pharmacol; 2006 May; 44(5):265-74. PubMed ID: 16545987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broad targeting of angiogenesis for cancer prevention and therapy.
    Wang Z; Dabrosin C; Yin X; Fuster MM; Arreola A; Rathmell WK; Generali D; Nagaraju GP; El-Rayes B; Ribatti D; Chen YC; Honoki K; Fujii H; Georgakilas AG; Nowsheen S; Amedei A; Niccolai E; Amin A; Ashraf SS; Helferich B; Yang X; Guha G; Bhakta D; Ciriolo MR; Aquilano K; Chen S; Halicka D; Mohammed SI; Azmi AS; Bilsland A; Keith WN; Jensen LD
    Semin Cancer Biol; 2015 Dec; 35 Suppl(Suppl):S224-S243. PubMed ID: 25600295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of pre-clinical and clinical studies targeting angiogenesis in pancreatic ductal adenocarcinoma.
    Craven KE; Gore J; Korc M
    Cancer Lett; 2016 Oct; 381(1):201-10. PubMed ID: 26723874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of angiogenesis in cancers.
    Pang RW; Poon RT
    Vasc Health Risk Manag; 2006; 2(2):97-108. PubMed ID: 17319453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.